Postpartum Hemorrhage Clinical Trial
Official title:
How's the Tone? Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections
Insufficient uterine tone resulting in atony can potentiate hemorrhage and adverse outcomes
for the parturient. Oxytocin is the first pharmacologic agent used, followed by
methylergonovine, carboprost, and misoprostol. The American Congress of Obstetricians and
Gynecologists (ACOG) recommends the sequential use of oxytocin, followed by methylergonovine,
carboprost, misoprostol, then surgical intervention for cases of refractory uterine atony.
Many studies have examined the effect and dosage of intravenous uterotonics, including
oxytocin.
Although there are anecdotal reports of using intravenous bolus or rapid infusion of
methylergonovine, no randomized trial has compared efficacy and side effects of these two
routes of administration. Investigators hypothesize that intravenous methylergonovine reduces
the time to adequate uterine tone (the tone at which the uterus is adequately contracted to
prevent atony after delivery of neonate), decreases the total dose of methylergonovine to
contract the uterus, and therefore produces fewer side effects of hypertension, nausea, and
vomiting. Reducing the time to achieve adequate uterine tone is likely to decrease postpartum
hemorrhage.
The United States is one of the few modern countries in which maternal peripartum mortality
continues to rise. One of the three most important causes of maternal mortality is severe
hemorrhage. Controlling postpartum uterine tone remains an important role for the obstetric
anesthesiologist. Insufficient uterine tone resulting in atony can potentiate hemorrhage and
adverse outcomes for the parturient. Oxytocin is the first pharmacologic agent used, followed
by methylergonovine, carboprost, and misoprostol. The American Congress of Obstetricians and
Gynecologists (ACOG) recommends the sequential use of oxytocin, followed by methylergonovine,
carboprost, misoprostol, then surgical intervention for cases of refractory uterine atony.
Many studies have examined the effect and dosage of intravenous uterotonics, including
oxytocin.
Methylergonovine maleate is a semi-synthetic ergot alkaloid. Methylergonovine(200 mcg) is
administered intramuscularly when oxytocin has been administered but has not contracted the
uterus sufficiently. It is not without side effects, however. Due to its vasoconstrictive
properties, methylergonovine has been shown to elevate blood pressures and is avoided in
preeclamptic patients who may not tolerate abrupt increases in blood pressures. Although
there are anecdotal reports of using intravenous bolus or rapid infusion of methylergonovine,
no randomized trial has compared efficacy and side effects of these two routes of
administration. Investigators hypothesize that intravenous methylergonovine reduces the time
to adequate uterine tone (the tone at which the uterus is adequately contracted to prevent
atony after delivery of neonate), decreases the total dose of methylergonovine to contract
the uterus, and therefore produces fewer side effects of hypertension, nausea, and vomiting.
Reducing the time to achieve adequate uterine tone is likely to decrease postpartum
hemorrhage.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03434444 -
In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol
|
N/A | |
| Terminated |
NCT01980173 -
Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
|
N/A | |
| Not yet recruiting |
NCT06033170 -
Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage
|
N/A | |
| Completed |
NCT02163616 -
Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study
|
Phase 3 | |
| Not yet recruiting |
NCT02319707 -
Management of the Third Stage of Labor
|
Phase 3 | |
| Recruiting |
NCT01600612 -
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
|
N/A | |
| Completed |
NCT02079558 -
Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section
|
Phase 2 | |
| Withdrawn |
NCT01108302 -
Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India
|
N/A | |
| Completed |
NCT00097123 -
RCT of Misoprostol for Postpartum Hemorrhage in India
|
N/A | |
| Completed |
NCT02883673 -
Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
|
N/A | |
| Completed |
NCT02542813 -
Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers
|
Phase 1 | |
| Completed |
NCT04201665 -
EMG for Uterotonic Efficiency Estimation
|
N/A | |
| Terminated |
NCT03246919 -
Ideal Time of Oxytocin Infusion During Cesarean Section
|
Phase 4 | |
| Not yet recruiting |
NCT05501106 -
Reducing Postpartum Hemorrhage After Vaginal Delivery
|
N/A | |
| Completed |
NCT05429580 -
Prophylactic Tranexamic Acid Use After Vaginal Delivery
|
N/A | |
| Terminated |
NCT03064152 -
Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery
|
N/A | |
| Recruiting |
NCT05382403 -
Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage
|
N/A | |
| Not yet recruiting |
NCT02853552 -
Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding
|
Phase 4 | |
| Completed |
NCT02910310 -
Introduction of UBT for PPH Management in Three Countries
|
N/A | |
| Completed |
NCT02805426 -
Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
|
Phase 4 |